Medical Transcription Billing Corp (NASDAQ:MTBC) Stock Price Jumps ahead of Earnings

The movement in MTBC stock price is likely due to an upward revision in the company’s revenue guidance for the year coupled with their Q2 financial release scheduled for tomorrow before the market opens.

Medical Transcription Billing Corp (NASDAQ:MTBC)

Medical Transcription Billing Corp (NASDAQ:MTBC) shareholders are enjoying a jump in their stock price of over 30% for the week. The movement in the stock price is likely due to an upward revision in the company’s revenue guidance for the year coupled with their Q2 financial release scheduled for tomorrow before the market opens. Volume for MTBC shares are on pace to exceed seven times their daily average. MTBC stock price chart:

Medical Transcription Billing Corp (NASDAQ:MTBC)
Candlebar stock price chart for MTBC

Before the July 27th announcement, management of Medical Transcription Billing Corp (NASDAQ:MTBC) provided revenue guidance for FY 2017 between $30 – $31 million. That guidance was revised on the 27th and is now pegged between $31 – $32 million. Those revised figures represent a 27% – 31% increase over FY 2016 figures.

Mahmud Haq, MTBC’s Chairman and CEO stated in the press release “We’re very pleased to see our revenue growth outpace our initial full year revenue guidance. Having also achieved our highest adjusted EBITDA as a public company during the second quarter of 2017, we anticipate a remarkable year of achievement for MTBC.”

Medical Transcription Billing Corp (NASDAQ:MTBC) shareholders have had a stellar run with the company. Over the past year, the stock price is up over 53% and is up over 120% YTD. Currently MTBC stock is trading just below $2 or over 500% its 52-week low of $0.29. Importantly, the stock has reached a Relative Strength Index figure of over 72. That level is normally associated with a stock that is overbought.

Medical Transcription Billing Corp (NASDAQ:MTBC) management will host a conference call at 8:30 a.m. EDT on Thursday, August 3, 2017, to discuss the first half 2017 results. The live webcast of the conference call can be accessed under Events & Presentations at or by dialing 412-317-5131 and referencing “MTBC Second Quarter 2017 Earnings Call.” A replay of the conference call will be available approximately one hour after conclusion of the call at the same link. An audio replay can also be accessed by dialing 412-317-0088 and providing access code 10110213.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $MTBC and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Medical Transcription Billing Corp (NASDAQ:MTBC) Explodes On 60% Revenue Growth And Healthcare Compliance Deal

Medical Transcription Billing Corp (NASDAQ:MTBC)

Medical Transcription Billing Corp (NASDAQ:MTBC) continues to post higher highs in the market days after announcing 60% year-over-year revenue growth. Investors also appear to be taking positions in the stock, on the company announcement of a new partnership with Healthcare Compliance Network LLC  – likely seen as another value-generating pathway.

MTBC-Healthcare Compliance Deal

Healthcare Compliance Network is a provider of compliance solutions mostly targeting hospitals and dispensaries in the US. Buoyed by the partnership Medical Transcription Billing Corp (NASDAQ:MTBC) senior vice president for of sales and marketing, Karl Johnson, says they will work together in coordinating marketing efforts as part of an effort that seeks to add value to each other’s service offerings.

“As a company that’s committed to compliance and industry leading revenue cycle management solutions, MTBC is a great fit for our customers. There are great synergies between our respective solutions and we look forward to working together,” said Wiks Moffat, Healthcare Compliance Principal.

While the partnership marks yet another milestone for the provider of cloud-based health care IT solutions fuelling interest in the stock is the fact that Medical Transcription Billing Corp (NASDAQ:MTBC) revenue appears to be growing faster than initially thought.

For the three months ending March 31, 2017, MTBC says its revenue, according to an unaudited report, should come in at $8.2 million. This would represent a 60% year over year increase, something that seems to have taken Wall Street by storm. The provider of health and cloud-based healthcare IT solutions also says its net loss and non-GAAP loss for the first quarter was significantly reduced compared to the fourth quarter.

Buoyed by the first quarter results, Chef executive officer, Mahmud Haq, remains confident of the company meeting its full year guidance. For the full year, the company expects revenue to be in the highs of $30 million. EBITDA, on the other hand, should come in at between $2 and $2.5 million. Last year Medical Transcription Billing Corp (NASDAQ:MTBC) posted revenues of $24.5 million representing a 6% growth from 2015.

Fuelling growth in revenue according to the chief executive is the company’s organic sales initiatives as well as acquisitions made over the past year.

Medical Transcription Billing Corp (NASDAQ:MTBC) is currently trading at highs of $1.22 share having rallied by 205% in Wednesday trading session. The big question now is whether the stock will be able to maintain the upward momentum ahead of the release of audited report.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: Monica Gray has an undergraduate degree in Accounting and an MBA – earned with Honors. She has six years of experience in the financial markets and has been a securities analyst for the past two years.